Anemia
Conditions
Keywords
advanced lung cancer, Procrit, Epoetin Alfa, Ferric Gluconate, iron supplementation
Brief summary
The purpose of this study is to find a better, more convenient way to improve anemia results by increasing the amount of medication given at 3 week intervals. Researchers want to know if giving a higher dose of Procrit® and intravenous (IV) iron once every 3 weeks would give better results in treating anemia without the need for more office visits.
Detailed description
There are more than 170,000 patients diagnosed with lung cancer in the United States each year and many will develop anemia (iron deficiency) during the course of treatment. Anemia is associated with poor quality of life and treatment delays for advanced lung cancer. The treatment of iron deficiency anemia is with iron. Iron is an essential mineral used in red blood cells to carry oxygen throughout the body. Iron is necessary to make hemoglobin, a key element in red blood cells. The FDA has approved Procrit® (epoetin alfa) to treat anemia in people with non-myeloid (bone marrow) malignancies. Procrit® is a man-made, injectable drug for treating anemia and it encourages red cell production. While the administration of intravenous iron therapy, injected into veins through an IV, did increase the response rate of Procrit® in a previous study, researchers want to find out the best amount of drug to use and the best time to administer Procrit®, along with ferric gluconate, (Ferrlecit®), added for lack of iron.
Interventions
DRUGEpoetin Alfa plus Iron
1. One (1) injection of Procrit®, by needle, inserted just under the skin; 2. 125 mg of ferric gluconate (an iron injection product), through an IV injection into a vein. These injections will take approximately 10-15 minutes to complete. Both will be administered every 3 weeks for a total of 4 cycles, unless the study doctor decides that a change in the amount of Procrit® and iron is necessary once the hemoglobin level rises or is above a certain amount. In addition to Procrit® and the intravenous iron, the subject will also receive platinum-containing chemotherapy every 3 weeks for 4 cycles as per standard of care for their lung cancer treatment. Radiation therapy will be allowed during this regimen if it is part of the subject's treatment plan.
Sponsors
James Graham Brown Cancer Center
University of Louisville
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed small cell or non small cell lung cancer * Stage III or Stage IV lung cancer * Platinum containing chemotherapy induced anemia (\< 10 g/dl Hb) * Cancer related anemia (\<10 g/dl Hb) at time of initiation of chemotherapy * ECOG performance status of 0,1, or 2 * Informed consent * Age\>18 * Expected to receive platinum based outpatient chemotherapy for at least nine weeks
Exclusion criteria
* Pregnant women * Intolerance to epoetin alfa or parenteral iron * More than 2 cycles of the planned platinum chemotherapy at time of enrollment * Chronic GI bleed (\> than 4 weeks positive hemoccult or gastroccult) * Ferritin \> 500 mg/dl * Anemia due to other causes than cancer or chemotherapy * Previous parenteral iron therapy * Uncontrolled hypertension (systolic BP \> 160, diastolic \> 100 mmHg)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Achieve hemoglobin responses > 2g/dl in at least 70% of patients | Nine weeks, after at least two doses of 120,000 units epoetin alfa |
Secondary
| Measure | Time frame |
|---|---|
| Descriptive evaluation of adverse effects of parenteral iron and epoetin alfa 120,000 units given every three weeks | Patient follow up until week 12 |
Countries
United States
Outcome results
None listed